In this TOGA Podcast, Australian medical oncologist, Associate Professor Chee Lee, St George Hospital, Kogarah, is joined by medical oncologist Dr Tristan Barnes, Royal North Shore Hospital, Sydney, and Dr Alex Davis, PhD candidate and medical oncologist at Chris O’Brien Lifehouse, Sydney. They discuss treatment of patients with non-small cell lung cancer with KRAS mutations, the role of co-mutations, and biomarkers that are negative predictors of response. Furthermore, the speakers give an update on current clinical research and approval status of KRAS inhibitors as well as the clinical need for the availability of KRAS inhibitors in Australia. Support TOGA

Thank you for listening to Conversations in Lung Cancer Research. If you

enjoyed this episode, please rate and review us on Apple Podcasts or

Spotify.

---------------

Connect with TOGA

Attend an Event: https://thoraciconcology.org.au/events/

Become a Member: Join the TOGA community at

https://thoraciconcology.org.au/membership/

Donate: Support our research and treatment initiatives at

https://thoraciconcology.org.au/support-us/donate/

Follow Us

LinkedIn:

https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/

X (Twitter): https://x.com/TOGAANZ

Instagram: https://www.instagram.com/togaanz/

YouTube:  https://www.youtube.com/@Thoracic_Oncology

---------------

Acknowledgement of Country

The Thoracic Oncology Group of Australasia Limited acknowledges

Traditional Owners of Country throughout Australia and recognises the

continuing connection to lands, waters and communities. We pay our

respect to Aboriginal and Torres Strait cultures; and to Elders past and

present.